Aurinia Pharmaceuticals Financial Ratios
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.65+0.43 (+2.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals ratio analysis
Aurinia Pharmaceuticals earned a net margin of 101.5% in FY 2025, up from 2.4% a year earlier. Gross margin was 88.5% compared with a median of 96.7% over the prior 6 years. Return on equity reached 49.4%, meaning Aurinia Pharmaceuticals generated 0.49 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Aurinia Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 7.42 | 213.50 | — | — | — | — | — | — | — | — |
| Price / sales | 7.29 | 5.20 | 7.34 | 4.57 | 64.88 | 32.69 | 6,031.93 | 1,215.88 | 833.59 | 428.32 |
| Price / book | 3.55 | 3.24 | 3.41 | 1.51 | 6.18 | 4.02 | 6.42 | 4.15 | 1.96 | 2.06 |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | — | — | — |
| Operating margin | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28,598.4% | -11,930.9% | -11,212.4% | -14,466.5% |
| Net margin | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27,794.0% | -11,464.1% | -16,935.9% | -13,465.3% |
| Free cash flow margin | 47.9% | 18.9% | -19.1% | -59.3% | -345.8% | -139.4% | -20,022.6% | -11,153.6% | -9,855.0% | -10,825.4% |
| Return on equity (ROE) | 49.4% | 1.5% | -20.6% | -26.7% | -37.8% | -25.2% | -29.6% | -39.1% | -39.8% | -64.8% |
| Return on assets (ROA) | 38.2% | 1.0% | -14.2% | -23.0% | -33.3% | -22.1% | -27.3% | -36.4% | -37.3% | -40.9% |
| Current ratio | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
| Revenue growth | 20.4% | 34.0% | 31.0% | 193.9% | -9.0% | 15,660.4% | -31.3% | 10.8% | 141.6% | — |
| EPS growth | 5,075.0% | — | — | — | — | — | — | — | — | — |